VanEck Associates’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-180,471
Closed -$21.8M 1481
2023
Q1
$21.8M Buy
180,471
+21,734
+14% +$2.5M 0.05% 230
2022
Q4
$18.2M Buy
158,737
+1,613
+1% +$178K 0.05% 254
2022
Q3
$15.9M Buy
157,124
+22,897
+17% +$2.42M 0.05% 254
2022
Q2
$13.6M Buy
134,227
+20,057
+18% +$2.19M 0.04% 282
2022
Q1
$13.3M Sell
114,170
-6,400
-5% -$740K 0.03% 312
2021
Q4
$13.8M Buy
+120,570
New +$13.8M 0.03% 310
2020
Q4
Sell
-95,036
Closed -$10.6M 1046
2020
Q3
$10.6M Buy
+95,036
New +$10.7M 0.03% 254

Other funds holding BSX.PRA

VanEck Associates's BSX.PRA Position: Q2 2023 in Review

VanEck Associates sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 180,471 shares — an estimated $21.8M sold.

VanEck Associates first reported a position in BSX.PRA in Q3 2020 and held it in 7 quarters. The position peaked at $21.8M in Q1 2023. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.

  • VanEck Associates reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
  • VanEck Associates sold 180,471 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $21.8M.
  • VanEck Associates first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q3 2020 and held it in 7 quarters.
  • VanEck Associates's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $21.8M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.

Based on VanEck Associates's 13F filing for Q2 2023, filed 3 Aug 2023.